SageMedic Corp.(SAGE), a Silicon Valley pioneer in Functional Precision Oncology, announces significant advancements in personalized cancer therapy using its innovative SAGE Oncotest™, a groundbreaking ex-vivo 3D microtumor assay that evaluates live tumor tissue responses to a comprehensive range of FDA-approved therapies. This novel approach is being presented at the American Association for Cancer Research (AACR) Annual Meeting, held in Chicago from April 25-30, 2025.
SAGE's recent findings, highlighted in a poster titled “Heterogeneity of ex-vivo Tumor Responses in Primary Ovarian Cancer Tissues,” demonstrate how every ovarian cancer is biologically distinct, with substantial variations in tumor responses to standard therapies like carboplatin and paclitaxel. The SAGE Oncotest™, uniquely capable of preserving the complexity of tumor heterogeneity and microenvironment, provides actionable insights within just 7-10 days-a critical step toward truly personalized cancer treatment. Unlike genomic tests that yield actionable results in only 26% of cases, the SAGE Oncotest™ delivers them in 88%.
“Our platform represents a transformative leap in Functional Precision Oncology,” stated Dr. Chris Apfel, Chair and CEO of SageMedic. “Every tumor is distinctively different, and genomic testing alone often fails to capture the full complexity of an individual patient's biology. Functional Precision Oncology measures how a patient's actual tumor responds to therapies. This enables SAGE concierge oncologists to personalize treatment, reduce toxic and ineffective drugs, and improve outcomes. This is especially vital for advanced cancer patients who have run out of options.”
In short, as a cornerstone of novel Functional Precision Oncology approaches, the SAGE Oncotest™-while not yet covered by insurance-provides a much-needed personalized option for late-stage cancer patients when standard of care treatments have failed, offering new hope where few options remain.
For more information, visit https://sagemedic.com/.
Media Contact:
Mara Quigley
661.255.8283
393991@email4pr.com
https://c212.net/c/img/favicon.png?sn=PH72236&sd=2025-04-24
View original content to download multimedia:https://www.prnewswire.com/news-releases/new-hope-for-advanced-cancer-patients-sage-showcases-treatment-matching-via-functional-precision-oncology-at-aacr-2025-302437344.html
SOURCE SageMedic Corp.
https://rt.newswire.ca/rt.gif?NewsItemId=PH72236&Transmission_Id=202504240832PR_NEWS_USPR_____PH72236&DateId=20250424